Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,500 shares, a drop of 70.0% from the March 31st total of 5,000 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 13,900 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Cocrystal Pharma in a research report on Thursday, April 4th.

Cocrystal Pharma Trading Up 3.0 %

Shares of COCP stock traded up $0.04 during trading hours on Friday, reaching $1.56. The stock had a trading volume of 29,490 shares, compared to its average volume of 13,389. The stock’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $1.63. Cocrystal Pharma has a 12 month low of $1.33 and a 12 month high of $3.29. The firm has a market capitalization of $15.81 million, a PE ratio of -0.78 and a beta of 1.34.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.13. As a group, equities research analysts anticipate that Cocrystal Pharma will post -2.31 EPS for the current fiscal year.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.